COMMON STOCK PURCHASE WARRANT LIXTE BIOTECHNOLOGY HOLDINGS, INC.Common Stock Purchase Warrant • November 1st, 2024 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [__] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [__], 2024 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [__], 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), up to [__] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT LIXTE BIOTECHNOLOGY HOLDINGS, INC.Security Agreement • July 20th, 2023 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations
THIS Placement Agent COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [●], 2023 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [●], 202[8] (the “Termination Date”), but not thereafter, to subscribe for and purchase from Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), up to [●] common shares, par value $0.0001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PRE-FUNDED COMMON STOCK PURCHASE WARRANT LIXTE BIOTECHNOLOGY HOLDINDS, INC.Pre-Funded Common Stock Purchase Warrant • November 1st, 2024 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [__] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from LIXTE BIOTECHNOLOGY HOLDINGS, INC., a Delaware corporation (the “Company”), up to [__] (as subject to adjustment hereunder, the “Warrant Shares”) of the common stock, par value $0.0001 per share, of the Company (“Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT LIXTE BIOTECHNOLOGY HOLDINGS, INC.Security Agreement • July 20th, 2023 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ___________or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on July 20, 2028 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), up to [●] common shares, par value $0.0001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 20th, 2023 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of July [18], 2023, between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
PLACEMENT AGENT WARRANT LIXTE BIOTECHNOLOGY HOLDINGS, INC.Placement Agent Agreement • November 1st, 2024 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, WallachBeth Capital LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [__], 2024 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [__], 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), up to [__] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
LIXTE BIOTECHNOLOGY HOLDINGS, INC. INDENTURE Dated as of __________, 20___Indenture • January 26th, 2021 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
Each party agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders of the Securities issued under this Indenture.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. COMMON STOCK SALES AGREEMENTSales Agreement • September 20th, 2021 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with WestPark Capital, Inc., as follows:
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 2nd, 2021 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of February 26, 2021, and is between Lixte Biotechology Holdings,, Inc, a corporation incorporated under the laws of the state of Delaware (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 8th, 2006 • SRKP 7 Inc • Blank checks
This Registration Rights Agreement (this “Agreement”) is made and entered into as of _______________, 2006, by and among SRKP 7, Inc., a Delaware corporation (the “Company”), on the one hand, and the purchasers signatory hereto (each such purchaser, a “Purchaser” and collectively, the “Purchasers”) and those shareholders of the Company listed on Exhibit A (the “Shareholders”), on the other hand.
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • June 8th, 2006 • SRKP 7 Inc • Blank checks • New York
AGREEMENT entered into as of the 17th day of May, 2006, by and between SRKP 7, Inc., a Delaware corporation with an address at 1900 Avenue of the Stars, Suite 310, Los Angeles, CA 90067 (the “Company”) and TMC Ulster Holdings Inc., a New York corporation with an address at 86 Ponche Terrace, Showkan, New York 12481 (the “Purchaser”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 1st, 2024 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
LIXTE BIOTECHNOLOGY HOLDINGS, INC. UNDERWRITING AGREEMENT 1,200,000 Units Consisting of 1,200,000 Shares of Common Stock And 1,200,000 Warrants to Purchase 1,200,000 Shares of Common StockUnderwriting Agreement • November 27th, 2020 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
LIXTE BIOTECHNOLOGY HOLDINGS, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WestPark Capital Inc. and WallachBeth Capital, LLC are acting as representatives (the “Representatives”), an aggregate of 1,200,000 Units (the “Firm Units”), each Firm Unit consisting of one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and one warrant to purchase one share of Common Stock (the “Warrants” and each a “Warrant”). The 1,200,000 shares of Common Stock referred to in this Section are hereinafter referred to as the “Firm Shares” and the Warrants referred to in this Section are hereinafter referred to as the “Firm Warrants,” and together with the Firm Units and the Firm Shares, the “Firm Securities.” The Firm Warrants shall be issued pursuant to, and shall have the rights and privil
LIXTE BIOTECHNOLOGY HOLDINGS, INC. UNDERWRITING AGREEMENT [*] Units Consisting of [*] Shares of Common Stock And [*] Warrants to Purchase [*] Shares of Common StockUnderwriting Agreement • November 16th, 2020 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
LIXTE BIOTECHNOLOGY HOLDINGS, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WestPark Capital Inc. is acting as representative (the “Representative”), an aggregate of [__] Units (the “Firm Units”), each Firm Unit consisting of one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and one warrant to purchase one share of Common Stock (the “Warrants” and each a “Warrant”). The [__] shares of Common Stock referred to in this Section are hereinafter referred to as the “Firm Shares” and the Warrants referred to in this Section are hereinafter referred to as the “Firm Warrants,” and together with the Firm Units and the Firm Shares, the “Firm Securities.” The Firm Warrants shall be issued pursuant to, and shall have the rights and privileges set forth in, a warrant agent agreeme
Placement Agency AgreementPlacement Agency Agreement • November 1st, 2024 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
WARRANT AGENT AGREEMENTWarrant Agent Agreement • November 27th, 2020 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
This Warrant Agent Agreement (“Warrant Agreement”) is made as of November 30, 2020, by and between Lixte Biotechnology Holdings, Inc., a Delaware corporation, with offices at 248 Route 25A, No.22 East Setauket, NY 11733 (the “Company”), and Computershare Inc., a Delaware corporation, and its wholly-owned subsidiary Computershare Trust Company N.A. a federally chartered trust company (collectively, the “Warrant Agent”).
LIXTE BIOTECHNOLOGY HOLDINGS, INC. UNDERWRITING AGREEMENT [*] Shares of Common StockUnderwriting Agreement • October 13th, 2020 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
LIXTE BIOTECHNOLOGY HOLDINGS, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WestPark Capital Inc. is acting as representative (the “Representative”), an aggregate of [*] authorized but unissued shares of common stock, par value $0.0001 per share, (the “Common Stock”) of the Company (the “Firm Shares”). The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 4 hereof, up to an additional [*] shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares” or the “Securities”.
EMPLOYMENT AGREEMENTEmployment Agreement • August 18th, 2020 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • Delaware
This Employment Agreement (“Agreement”) is entered into as of August 12, 2020 by and between Lixte Biotechnology Holdings Inc., a Delaware corporation having its principal place of business located at 248 Route 25A, No. 2, East Setauket, NY 11733 (“Company”), and Robert N. Weingarten (“Employee”), an individual residing at 5439 Lockhurst Dr., Woodland Hills, CA 91367.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 10th, 2017 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT this (“Agreement”), dated as of April 3, 2017, by and among Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and Hung Tak Ho (“Purchaser”).
SERVICES AGREEMENT between LIXTE BIOTECHNOLOGY, INC. and Freestate of Bavaria Represented by UNIVERSITY OF REGENSBURG for its Institute of Pathology, Franz- Josef-Strauss-Alle 11, D-93053 RegensburgServices Agreement • March 13th, 2007 • Lixte Biotechnology Holdings, Inc. • Blank checks
This Agreement is made as of the 5th day of January, 2007 (the “Effective Date”), between Lixte Biotechnology, Inc., a Delaware corporation having its principal place of business at 248 Route 25A #2, East Setauket, New York 11733, United States of America (“Lixte”), and The Free State of Bavaria, represented by the University of Regensburg, a German entity having its principal place of business at 93040 Regensburg, Germany, in turn represented by the Head of Administration (“University”).
STOCK OPTION AGREEMENTStock Option Agreement • November 14th, 2007 • Lixte Biotechnology Holdings, Inc. • Blank checks • Delaware
THIS STOCK OPTION AGREEMENT (“Agreement”) is made by and between LIXTE BIOTECHNOLOGY HOLDINGS, INC, a Delaware corporation (the “Company”), and FRANCIS JOHNSON (the “Optionee”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • December 30th, 2015 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
THIS AGREEMENT is made and entered into as of December 25, 2015 (hereinafter “EFFECTIVE DATE”) by and between Lixte Biotechnology Holdings, Inc. a Delaware corporation, whose address is 248 Route 25A, No. 2, East Setauket, NY 11733 (hereinafter “LICENSOR”) and Taipei Medical University, an institution with a place of business at 250 Wuxing Street, Taipei City, Taiwan 110 ((hereinafter “LICENSEE”).
STOCK OPTION AGREEMENTStock Option Agreement • November 14th, 2007 • Lixte Biotechnology Holdings, Inc. • Blank checks • Delaware
THIS STOCK OPTION AGREEMENT (“Agreement”) is made by and between LIXTE BIOTECHNOLOGY HOLDINGS, INC, a Delaware corporation (the “Company”), and STEPHEN K. CARTER (the “Optionee”).
Collaboration Agreement between the Company and BioPharmaWorks LLCCollaboration Agreement • September 18th, 2015 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
THIS COLLABORATION AGREEMENT (this “Agreement”) is made and entered into as of September __, 2015 (the “Effective Date”), by and between Lixte Biotechnology Holdings, Inc., a Delaware corporation (“Lixte”) and BioPharmaWorks LLC, a Connecticut limited liability company (“BioPharma”) with reference to the following:
AMENDMENTAmendment • May 14th, 2008 • Lixte Biotechnology Holdings, Inc. • Blank checks
This Amendment (the “Amendment”) is made as of January 29, 2008 between Lixte Biotechnology Holdings, Inc., a Delaware corporation (“Lixte”), and Chem-Master International, Inc., a New York corporation (“Chem-Master”), with reference to the following:
ADVISORY AGREEMENTAdvisory Agreement • March 21st, 2014 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
This ADVISORY AGREEMENT (this “Agreement”), is entered into effective as of January 1, 2014, by and between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and Kathleen Mullinix (“Advisor”).
AGREEMENT between LIXTE BIOTECHNOLOGY HOLDINGS, INC. and CHEM-MASTER INTERNATIONAL, INC.Agreement • February 9th, 2007 • Lixte Biotechnology Holdings, Inc. • Blank checks • New York
This Agreement is made as of the 5th day of February, 2007, (the “Effective Date”), between Lixte Biotechnology Holdings, Inc., a Delaware corporation having its principal place of business at 248 Route 25A #2, East Setauket, New York 11733, United States of America (“Lixte”), and Chem-Master International, Inc., a New York corporation having its principal place of business at P.O. Box 563, East Setauket, New York 11733, United States of America (“Chem-Master”).
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • March 21st, 2014 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • Arizona
THIS AGREEMENT (the “Agreement”) is made and entered into this 24th day of December, 2013 (the “Effective Date”) between Lixte Biotechnology Holdings, Inc., 248 Route 25A No. 2, East Setauket, New York 11733 (hereinafter referred to as the “Company”), and NDA Consulting Corp., an Arizona corporation, with offices at 9977 N. 90th Street, Suite 175, Scottsdale, Arizona 85258 (hereinafter referred to as the “Consultant”).
SECOND AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • March 29th, 2023 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations
This Second Amendment (the “Amendment”) to Employment Agreement is made as of November 6, 2022 (the “Amendment Date”) between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and Eric Forman (“Employee”) with reference to the following:
NATIONAL INSTITUTES OF HEALTH MATERIALS COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENTMaterials Cooperative Research and Development Agreement • March 21st, 2014 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations
This Materials Cooperative Research and Development Agreement (“M-CRADA”) has been adopted for use by the Institutes and Centers (“ICs”) of the National Institutes of Health (“NIH”) for transfers of essential research material(s) from collaborators (hereinafter “Collaborator Research Material”) not otherwise reasonably available for NIH research. It consists of a copy of the NIH Model M-CRADA, a Signature Page, a Contacts Page, and a Summary Page. The research plan (“Research Plan”) is attached as Appendix A and all changes to this model agreement are collected in Appendix B. Appendices A and B are incorporated herein by reference. This M-CRADA involves no exchange of personnel or of any resources other than as described in Appendix A. This M-CRADA is made under authority of the Federal Technology Transfer Act, 15 U.S.C. § 3710a, and is governed by its terms.
COLLABORATION AGREEMENT FOR AN INVESTIGATOR-INITIATED CLINICAL TRIALCollaboration Agreement • August 6th, 2019 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • Madrid
On the one hand, Grupo Español de Investigación en Sarcomas (GEIS) with tax identification number G81890212, and address at C/ Diego de Leon 47, 28006 Madrid, Spain (hereinafter the “Sponsor”) represented in this act by Dr. Claudia Valverde Morales, in her capacity as President.
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENTCooperative Research and Development Agreement • January 23rd, 2007 • Lixte Biotechnology Holdings, Inc. • Blank checks • District of Columbia
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVE COVER PAGEPatent License Agreement • March 31st, 2009 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:
SHARE EXCHANGE AGREEMENTShare Exchange Agreement • July 7th, 2006 • SRKP 7 Inc • Blank checks
THIS SHARE EXCHANGE AGREEMENT, dated as of the 8th day of June, 2006 (the “Agreement”), by and among SRKP 7, Inc., a Delaware corporation (the “Company”); John S. Kovach (“Seller”); and Lixte Biotechnology, Inc., a Delaware corporation (“Lixte”). The Company, Seller and Lixte are collectively referred to herein as the “Parties”.
CLINICAL TRIAL RESEARCH AGREEMENTClinical Trial Research Agreement • August 23rd, 2018 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations
This CLINICAL TRIAL RESEARCH AGREEMENT (this “AGREEMENT”) is entered into on August 20, 2018 (the “Effective Date”), by and between H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., with a primary location at 12902 Magnolia Drive, Tampa, FL 33612-9497, hereinafter called “INSTITUTION,” and Lixte Biotechnology Holdings, Inc., with its office and place of business at 248 Route 25A, No. 2, East Setauket, NY, hereinafter called “LIXTE.” (“INSTITUTION” and “LIXTE”, each referred to as a “Party” and together, “Parties”)
